Remacemide

Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research[1][2][3][4].

Product Specifications

CAS Number

[128298-28-2]

Product Name Alternative

FPL 12924; PR 934-423; FPL 13592

UNSPSC

12352005

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/remacemide.html

Purity

99.88

Solubility

DMSO : 87.5 mg/mL (ultrasonic)

Smiles

O=C(CN)NC(C)(CC1=CC=CC=C1)C2=CC=CC=C2

Molecular Formula

C17H20N2O

Molecular Weight

268.35

References & Citations

[1]Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9 (4) :871-83.|[2]Dyker AG, et al. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30 (9) :1796-801.|[3]Greenamyre JT, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35 (6) :655-61. |[4]Kieburtz K, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord. 1996 May;11 (3) :273-7.